Oppenheimer reiterates Climb Bio stock rating on SLE data
Covered in this story
What has happened since
- Climb Bio is up 0.7% since this was published, 8 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Oppenheimer’s $25 target on $CLYM is on the record and being tracked to Nov 2027 (12-month default), scored on the close that day.
Oppenheimer’s track record →Analyst targets on Climb Bio
- Wedbush: at $10.1 · target $27 by Nov 2027 · Outperform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CLYM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Climb Bio →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.